ReCLAIM-2
Dry Age-Related Macular Degeneration

A phase 2, randomized, double-masked, placebo-controlled clinical study to evaluate the safety, efficacy and pharmacokinetics of subcutaneous injections of elamipretide in subjects with dry age-related macular degeneration (AMD) with geographic atrophy (GA).

PARTICIPANTS
The trial will assess approximately 180 patients who have at least 1 eye with dry AMD with GA.

TRIAL SITES
40 sites in the United States

TRIALBegan
Q1 2019

ENDPOINTS

PRIMARY
- Safety and tolerability
- Low-luminance best-corrected visual acuity

SECONDARY
- Low-luminance reading acuity
- Best-corrected visual acuity
- GA area as measured by fundus autofluorescence
- GA area as measured by optical coherence tomography

Over 10M Americans are impacted by AMD

For more information, please visit ClinicalTrials.gov.